LCTX:NYSEAMERICAN
Lineage Cell Therapeutics Inc
US$1,22
arrow_upward
+0,83%(+0,0100) 1 HR
US$1,22
0,00% (0,00)
bedtimeSetelah jam perdagangan normal
Tutup: 14 Jul, 16.00.00 GMT-4 · USD
search
Semua simbol
1 HR
5 HR
1BLN
6BLN
YTD
1THN
5THN
MAKS
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk LCTX...
Buka
US$1,22
Tinggi
US$1,24
Rendah
US$1,21
Kapitalisasi pasar
304,14 jt
Volume rata-rata
1,80 jt
Volume
770,56 rb
Harga tinggi dalam 52 minggu terakhir
US$2,09
Harga rendah dalam 52 minggu terakhir
US$0,93
EPS
-US$0,28
Beta
1,51
Saham beredar
249,30 jt
Jumlah karyawan
75
Buka
US$1,22
Tinggi
US$1,24
Rendah
US$1,21
Kapitalisasi pasar
304,14 jt
Volume rata-rata
1,80 jt
Volume
770,56 rb
Harga tinggi dalam 52 minggu terakhir
US$2,09
Harga rendah dalam 52 minggu terakhir
US$0,93
EPS
-US$0,28
Beta
1,51
Saham beredar
249,30 jt
Jumlah karyawan
75
Artikel berita
Dari berbagai sumber di seluruh web
Stock Titan
·
1 hari yang lalu
New COR1 cell therapy aims to ease global shortage of corneal transplants
www.dars.gov.et
·
3 minggu yang lalu
LCTX Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances Pipeline - Capex Guidance
Profil
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Tentang Lineage Cell Therapeutics Inc
Konten AI mungkin berisi kesalahan. Pelajari lebih lanjut